EMA Authorised: Ibandronic Acid Sandoz (ibandronic acid) — Sandoz GmbH

View source ↗

Summary

The EMA authorised Ibandronic Acid Sandoz (ibandronic acid) for indications including breast neoplasms, neoplasm metastasis, and fractures due to bone condition…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Fractures Bone
• Neoplasm Metastasis

Drugs mentioned

• Ibandronic Acid Sandoz (ibandronic acid)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Neoplasm Metastasis;Fractures, Bone. MAH: Sandoz GmbH. Decision date: 06/07/2022